Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied

Frontiers in Cardiovascular Medicine

Leo Ungar¹ 

关键词: familial hypercholesterolemia (FH);    percutaneous coronary intervention (PCI);    statins;    PCSK9 inhibitors;    revascularization in familial hypercholesterolemia;    familial hypercholesterolemia registry;    LDL receptor;    FH diagnostic criteria;   

DOI  :  10.3389/fcvm.2018.00116

学科分类：心脏病和心血管学

来源: Frontiers

【 摘 要 】

Familial hypercholesterolemia (FH) is a common heritable condition in which mutations of genes governing cholesterol metabolism result in elevated LDL levels and accelerated atherosclerosis. The treatment of FH focuses on lipid lowering drugs to decrease patients' cholesterol levels and reduce their risk of cardiovascular events. Even with optimal medical therapy, some FH patients will develop coronary atherosclerosis, suffer myocardial infarction, and require revascularization. Yet, the revascularization of FH patients has not been widely studied. Here we review FH, identify unanswered questions in the interventional management of FH patients, and explore barriers and opportunities for answering these questions. Further research is needed in this neglected but important topic in interventional cardiology.

【 授权许可】

CC BY